Aerovate Therapeutics Stock Downgraded After Trial Setback
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
- Latest
- Trending
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Starboard met Autodesk execs, urging margin boosts, board changes, and transparency on a recent accounting probe that hit stock. No ...
BTC dips as Fed holds rates, inflation remains a focus. Trump leads Biden narrowly in latest polls; Kennedy at 9.2% ...
CMCC launches a Manufacturing Tech program with General Dynamics Bath Iron Works, offering job interviews for qualified graduates. Contact Kerry ...
The UK elections on July 4 are seen as a test for poll security amid rising cyber threats, with advanced ...
Polygon NFTs surge with Moon Girl; BlockDAG presale hits $50.4M; Sheldon The Sniper and Bluntz bullish on BNB. Join BlockDAG ...
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Raymond James Financial appoints Alex David to lead independent financial advisors in the Northeast, strengthening their services in the region.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.